These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19920792)

  • 1. The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern of cardiovascular safety?
    McIvor RA
    Pol Arch Med Wewn; 2009 Nov; 119(11):697-8. PubMed ID: 19920792
    [No Abstract]   [Full Text] [Related]  

  • 2. Tiotropium versus salmeterol in COPD.
    Oba Y
    N Engl J Med; 2011 Jun; 364(26):2553; author reply 2553-4. PubMed ID: 21714654
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are there cardiovascular adverse effects of inhaled anticholinergics?].
    Nagy LB
    Orv Hetil; 2015 Aug; 156(31):1246-52. PubMed ID: 26211748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiovascular risk of tiotropium: is it real?
    Cazzola M; Calzetta L; Matera MG
    Expert Opin Drug Saf; 2010 Sep; 9(5):783-92. PubMed ID: 20565229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2008 Sep; 300(12):1439-50. PubMed ID: 18812535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
    Kesten S; Leimer I; Jara M
    JAMA; 2009 Mar; 301(12):1224; author reply 1225-6. PubMed ID: 19318648
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
    Oba Y
    JAMA; 2009 Mar; 301(12):1223; author reply 1225-6. PubMed ID: 19318646
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
    Covelli HD
    JAMA; 2009 Mar; 301(12):1223; author reply 1225-6. PubMed ID: 19318645
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
    Hodgin KE; Maloney JP
    JAMA; 2009 Mar; 301(12):1224; author reply 1225-6. PubMed ID: 19318647
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safety of tiotropium therapy in chronic obstructive lung diseases (COPD)].
    Osztovits J; Fehér J
    Orv Hetil; 2010 May; 151(18):749-50. PubMed ID: 20410002
    [No Abstract]   [Full Text] [Related]  

  • 11. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.
    Salpeter SR
    Drugs; 2009 Oct; 69(15):2025-33. PubMed ID: 19791824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Tiotropium and the treatment of chronic obstructive lung disease.
    Ann Intern Med; 2005 Sep; 143(5):I20. PubMed ID: 16144886
    [No Abstract]   [Full Text] [Related]  

  • 13. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
    Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
    Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How safe are anticholinergics in patients with COPD?
    Hew MJ; Sestini P; Irving LB
    Med J Aust; 2009 May; 190(9):468-9. PubMed ID: 19413514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability and risk benefit analysis of tiotropium in COPD.
    Oba Y; Zaza T; Thameem DM
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):575-84. PubMed ID: 19281075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anticholinergics and their cardiovascular effects--between fear and reality].
    Mihălţan F; Ulmeanu R
    Pneumologia; 2010; 59(2):107-8. PubMed ID: 20695368
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium.
    O'Connor AB
    Ann Intern Med; 2006 Jan; 144(2):148; author reply 148-9. PubMed ID: 16418423
    [No Abstract]   [Full Text] [Related]  

  • 18. Tiotropium: a potential replacement for ipratropium in patients with COPD.
    Shukla VK
    Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium.
    Good CB; Longo L
    Ann Intern Med; 2006 Jan; 144(2):147; author reply 148-9. PubMed ID: 16418422
    [No Abstract]   [Full Text] [Related]  

  • 20. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease.
    Panning CA; DeBisschop M
    Pharmacotherapy; 2003 Feb; 23(2):183-9. PubMed ID: 12587807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.